<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179579</url>
  </required_header>
  <id_info>
    <org_study_id>HIPEC-02</org_study_id>
    <nct_id>NCT03179579</nct_id>
  </id_info>
  <brief_title>Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer</brief_title>
  <official_title>A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Systemic Chemotherapy And Cytoreductive Surgery (CRS) in the Treatment of Peritoneal Carcinomatosis From Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shu-Zhong Cui</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southern Medical University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a multi-center, prospective, randomized controlled clinical observation the&#xD;
      safety and efficacy that stage IV limited peritoneal metastasis of gastric cancer patients&#xD;
      accept hyperthermic intraperitoneal chemotherapy plus neoadjuvant chemotherapy with CRS and&#xD;
      systemic chemotherapy. With advanced-stage gastric patients of confined to the peritoneal as&#xD;
      the research object, with median progression-free survival and overall survival, adverse&#xD;
      events as the end points.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneal metastases in gastric cancer are considered as terminal disease with poor&#xD;
      prognosis, the median survival time of this kind of patients is less than 1 year and even&#xD;
      worse in China. Recently, cytoreductive surgery (CRS) combined with hyperthermic&#xD;
      intraperitoneal chemotherapy (HIPEC) has been suggested to improve survival in patients with&#xD;
      peritoneal metastases from gastric cancer. Even though the REGATTA trial demonstrated that&#xD;
      the removal of the primary tumor is not necessarily beneficial, the role of operation aiming&#xD;
      at R0 resection combined with new regimens like HIPEC and new chemotherapeutic agents is&#xD;
      still confusing. Neoadjuvant chemotherapy prolonged OS of patients received macroscopically&#xD;
      radical (CC0) surgery. Compared to systemic chemotherapy, HIPEC promotes chemotherapy to&#xD;
      penetrate deeper into the cancer tissue, which needed multicenter randomized clinical trials&#xD;
      (RCTs) to comfirm. Therefore, we has conducting prospective phase III trial of HIPEC combined&#xD;
      with systemic chemotherapy and CRS for gastric cancer with peritoneal metastasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>assess median overall survival rate during 3 years in both study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for morbidity and mortality</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>determine percent of patients wtih Grade I-IV adverse events according to NCI criteria, Common Terminology Criteria for AE (CTCAE 4.0).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession&#xD;
2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks&#xD;
Cytoreductive surgery&#xD;
HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession&#xD;
4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks&#xD;
Cytoreductive surgery&#xD;
4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HIPEC with neoadjuvant chemotherapy</intervention_name>
    <description>HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>CRS with HIPEC and adjuvant cheomtherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systemic chemotherapy</intervention_name>
    <description>NACT 3 cycles +CRS +ACT 4-6 cycles</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>CRS with systemic chemotherpay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gastic adenocarcinoma is diagnosed by histological and cytological examination.&#xD;
&#xD;
          2. Peritoneal carcinomastosis of gastric cancer is diagnosed by laparotomy or&#xD;
             laparoscopic exploration.&#xD;
&#xD;
          3. According to Sugarbaker's peritoneal cancer index (PCI), PCI score of participant is&#xD;
             no more than 20.&#xD;
&#xD;
          4. 18 &lt; Age &lt; 70 year old&#xD;
&#xD;
          5. Expected survival &gt; 3 months&#xD;
&#xD;
          6. Performance status: ECOG 0-1&#xD;
&#xD;
          7. Adequate bone marrow function Hb ≥9 g/dl (After correction in case of iron deficient&#xD;
             anemia) WBC ≥ 3,500/mm3, Platelet ≥ 100,000/mm3&#xD;
&#xD;
          8. Adequate renal function Creatinine ≤ 1.5 mg/dl, and adequate hepatic function&#xD;
             Bilirubin ≤ 1.5 mg/dl and AST and ALT ≤ 2.5×ULN&#xD;
&#xD;
        10. Voluntary participation after getting written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Except for peritoneal carcinomatosis, gastric cancer concurrently metastasized to&#xD;
             liver, lung, para-aortic lymph node and other distant organs.&#xD;
&#xD;
          2. Extensive adhesion in peritoneal cavity&#xD;
&#xD;
          3. Previous History of other malignancies&#xD;
&#xD;
          4. Poorly controlled disease e.g. atrial fibrillation, stenocardia, cardiac&#xD;
             insufficiency, persistent hypertension despite medicinal treatment, ejection&#xD;
             fraction&lt;50%&#xD;
&#xD;
          5. Receiving other chemotherapy, radiotherapy or immunotherapy&#xD;
&#xD;
          6. Patients who are unsuitable candidates by doctor's decision&#xD;
&#xD;
          7. Without given written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu-Zhong Cui, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xian-Zi Yang, M.D</last_name>
    <phone>8602066673666</phone>
    <email>7097359@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhen Tang, M.M</last_name>
    <phone>8602066673666</phone>
    <email>tangzhentangmin@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xianzi Yang, M.D</last_name>
      <phone>8602066673666</phone>
      <email>7097359@qq.com</email>
    </contact>
    <investigator>
      <last_name>shuzhong cui, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Shu-Zhong Cui</investigator_full_name>
    <investigator_title>President of Affiliated Tumor Hospital of Guangzhou Medical</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Peritoneal Carcinomatosis</keyword>
  <keyword>Hyperthermic Intraperitoneal Chemotherapy</keyword>
  <keyword>Systemic Chemotherapy</keyword>
  <keyword>Cytoreductive Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

